Research
Weight regain after stopping GLP-1: the evidence
Two withdrawal trials — STEP 4 (semaglutide) and SURMOUNT-4 (tirzepatide) — consistently show that stopping a GLP-1 leads to substantial weight regain
Two withdrawal trials — STEP 4 (semaglutide) and SURMOUNT-4 (tirzepatide) — consistently show that stopping a GLP-1 leads to substantial weight regain, while continuing preserves the loss. Regain is driven by the return of appetite signals, not by behavior, which reframes GLP-1 therapy as long-term for most people.
What the trials establish
The regain evidence is unusually clean because both trials used a randomized withdrawal design: reach a lower weight on the drug, then continue or switch to placebo. In both, the placebo groups regained a large share of the lost weight within about a year.
Mechanistically, GLP-1 drugs suppress appetite while present; remove them and the appetite drive returns. This is why 'kickstart then stop' strategies tend to disappoint, and why off-ramping is an individualized clinical decision rather than a published taper.
For the cost conversation, regain is the decisive fact: if maintaining results means continued treatment, the number that matters is sustained monthly cost over years, not an introductory rate.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| STEP 4 | Adults with overweight/obesity after 20-week run-in | 803 | Continuing lost further weight; switching to placebo regained substantial weight | Rubino D, et al. JAMA 2021;325(14):1414-1425 | NCT03548987 · PMID 33755728 · DOI |
| SURMOUNT-4 | Adults with obesity after lead-in | 670 | Continued treatment maintained loss; withdrawal led to regain | Aronne LJ, et al. JAMA 2024;331(1):38-48 | NCT04660643 · PMID 38078870 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Do people regain weight after stopping?
Yes — STEP 4 and SURMOUNT-4 both show substantial regain after withdrawal.
Is regain avoidable?
Continued treatment preserves loss; any stop should be planned with a prescriber.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.